

This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

BUSY WEEK? Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director **Patricia Van Arnum**.

Sponsored By:



Spectrum Offers 1200+ USP/NF cGMP Products.
Order Your 2016 USP Catalog!



[Click Here](#)

1. [Novo Nordisk Breaks Ground on \\$1.8 Billion US Manufacturing Facility](#)

Novo Nordisk has broken ground on a new \$1.8 billion diabetes medicine production facility in Clayton, North Carolina. The facility will produce active pharmaceutical ingredients for Novo Nordisk's current and future GLP-1 and insulin medicines and is expected to be fully operational in 2020. [Read More](#)

2. [BMS To Acquire Padlock Therapeutics in \\$600 Million Deal](#)

Bristol-Myers Squibb has agreed to acquire Padlock Therapeutics, Inc. a privately held, Cambridge, Massachusetts-based biotechnology company focused on developing treatments for autoimmune diseases. The transaction includes upfront and near-term contingent milestone payments of up to \$225 million and additional contingent consideration of up to \$375 million upon the achievement by Bristol-Myers Squibb of certain development and regulatory events. [Read More](#)

3. [BMS, NIBRT Collaborate on Biomanufacturing Training](#)

Bristol-Myers Squibb has formed a collaboration with the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland for a process science and technology laboratory that will strengthen productivity of manufacturing processes for biologics. The collaboration comes ahead of Bristol-Myers Squibb's plans to open a new EUR 900 million (\$1.02 billion) large-scale biologics manufacturing facility in Cruiserath, County Dublin. [Read More](#)

4. [Daiichi Sankyo Plans to Close API Plant in Japan](#)

Daiichi Sankyo Company, Limited announced its decision to close its active pharmaceutical ingredient (API) and intermediates manufacturing plant in Hiratsuka, Japan. The plant, which employs 150 people, is owned by its subsidiary, Daiichi Sankyo Chemical Pharma Co., Ltd. [Read More](#)

5. [GSK Sets Forth IP Policy to Increase Access in Developing Countries](#)

In line with the meeting of the United Nations High Level Panel on Access to Medicines, GlaxoSmithKline CEO Sir Andrew Witty has set out a series of steps designed to increase access of GSK medicines to developing countries through a graduated approach to filing and enforcing patents so that intellectual property protection reflects a country's economic maturity. [Read More](#)

6. [Grifols To Invest \\$360 Million in Manufacturing Expansions](#)

The board of directors of Grifols has approved a plan for new industrial investments for the Bioscience Division for the period 2016-2021, with the goal of expanding manufacturing capacity for plasma-derived products. The company plans to invest \$360 million to increase plasma fractionation capacity and purification of several proteins. [Read More](#)

7. [Bayer, Regeneron Sign Pact for Eye Care Combo Therapy](#)

Bayer and Regeneron Pharmaceuticals will jointly develop a combination therapy of the angiopoietin2 antibody, nesvacumab, and the vascular endothelial growth factor trap, aflibercept, for the treatment of serious eye diseases. [Read More](#)

8. [FDA OKs Lilly's Psoriasis Drug Taltz](#)

The US Food and Drug Administration has approved Eli Lilly and Company's Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis, marking the company's first new molecular entity approved thus far in 2016. [Read More](#)

9. [PuraCap, Humanwell Healthcare To Acquire Epic Pharma for \\$550 Million](#)

Humanwell Healthcare Group, a Chinese life sciences company, and PuraCap Pharmaceutical LLC, a South Plainfield, New Jersey pharmaceutical company, have agreed to acquire 100% of the membership interests of Epic Pharma, LLC of Laurelton, New York for \$550 million. The move further positions Humanwell and PuraCap in the US generics market and expands their existing commercial and manufacturing capabilities, including a new controlled substance manufacturing facility. [Read More](#)

10. [Brammer Bio Launches as a New Biologics CDMO](#)

Brammer Biopharmaceuticals has merged with Florida Biologix to create a cell and gene therapy biologics contract development and manufacturing organization. The merged company, Brammer Bio, will provide process development, clinical manufacturing, and commercial manufacturing. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599
www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org